VolitionRX (NYSEAMERICAN:VNRX) Stock Passes Below 50-Day Moving Average – Should You Sell?

VolitionRX Limited (NYSEAMERICAN:VNRX)’s share price passed below its 50-day moving average during trading on Friday . The stock has a 50-day moving average of $3.17 and traded as low as $2.76. VolitionRX shares last traded at $3.13, with a volume of 513,751 shares changing hands.

Analysts Set New Price Targets

VNRX has been the topic of several research reports. HC Wainwright lowered their price objective on shares of VolitionRX from $30.00 to $20.00 and set a “buy” rating on the stock in a research report on Thursday, April 2nd. Citigroup cut shares of VolitionRX to a “hold” rating in a research report on Monday, April 20th. Finally, D. Boral Capital restated a “hold” rating on shares of VolitionRX in a research report on Monday, April 20th. One analyst has rated the stock with a Strong Buy rating, one has issued a Buy rating and three have issued a Hold rating to the stock. According to data from MarketBeat, the company has a consensus rating of “Moderate Buy” and a consensus target price of $46.67.

VolitionRX Stock Performance

The company has a market cap of $26.07 million, a PE ratio of -0.75 and a beta of 1.03. The business’s 50-day moving average is $3.17 and its 200 day moving average is $4.75.

VolitionRX (NYSEAMERICAN:VNRX) last released its quarterly earnings data on Thursday, May 14th. The medical research company reported ($0.97) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.70) by ($0.27). The business had revenue of $0.99 million for the quarter, compared to analysts’ expectations of $1.52 million. Equities research analysts anticipate that VolitionRX Limited will post -2.4 EPS for the current fiscal year.

Hedge Funds Weigh In On VolitionRX

A number of hedge funds have recently modified their holdings of the company. Lagoda Investment Management L.P. increased its position in shares of VolitionRX by 6.7% in the third quarter. Lagoda Investment Management L.P. now owns 12,487,000 shares of the medical research company’s stock valued at $8,476,000 after acquiring an additional 782,000 shares during the period. Armistice Capital LLC increased its position in shares of VolitionRX by 10.4% in the third quarter. Armistice Capital LLC now owns 9,380,425 shares of the medical research company’s stock valued at $6,367,000 after acquiring an additional 887,351 shares during the period. Geode Capital Management LLC increased its position in shares of VolitionRX by 9.8% in the fourth quarter. Geode Capital Management LLC now owns 963,986 shares of the medical research company’s stock valued at $246,000 after acquiring an additional 85,816 shares during the period. Citadel Advisors LLC increased its position in shares of VolitionRX by 70.1% in the third quarter. Citadel Advisors LLC now owns 329,520 shares of the medical research company’s stock valued at $224,000 after acquiring an additional 135,775 shares during the period. Finally, Squarepoint Ops LLC purchased a new position in shares of VolitionRX in the fourth quarter valued at about $34,000. Hedge funds and other institutional investors own 8.09% of the company’s stock.

About VolitionRX

VolitionRX, traded as VNRX on the NYSE American exchange, is a pioneering life sciences company focused on the development and commercialization of minimally invasive diagnostic tests for the early detection of cancer and other diseases. Utilizing proprietary technology to analyze circulating nucleosomes in blood samples, the company’s platform identifies disease-specific epigenetic and biochemical signatures. By offering blood-based screening solutions, VolitionRX aims to deliver alternatives to invasive, costly and time-consuming procedures, potentially improving patient outcomes through earlier diagnosis.

The company’s flagship product suite, branded as Nu.Q, comprises assays designed to detect biomarkers associated with a range of malignancies, including colorectal, lung and pancreatic cancers, as well as other systemic conditions.